找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Lebensqualit?t im Alter; Generationenbeziehun Andreas Motel-Klingebiel (Dr.),Hans-Joachim Kondra Book 2002 Springer Fachmedien Wiesbaden 20

[復(fù)制鏈接]
31#
發(fā)表于 2025-3-26 23:03:00 | 只看該作者
32#
發(fā)表于 2025-3-27 03:23:41 | 只看該作者
r the use in parasitology (He?mánek and Prokopi? 1989). In this study we investigated the possibility of thymic preparations to influence the resistance to model parasite infections (2 helminthoses — cysticercosis and ascaridosis and 2 protozooses — coccidiosis and cryptosporidiosis) in intact and i
33#
發(fā)表于 2025-3-27 07:59:59 | 只看該作者
34#
發(fā)表于 2025-3-27 12:38:34 | 只看該作者
Betina Hollsteintoxic side effects (Schumann and others, 1989). Reduction of toxicity may be accomplished by encapsulation of MTPPE in liposomes, which are taken up preferably by the cells of the MPS. The question is whether liposome-encapsulated MTPPE (LE-MTPPE) retains its activity. LE-MTPPE has proven to be bene
35#
發(fā)表于 2025-3-27 16:16:28 | 只看該作者
Jan Marbachsing nodal regions that may not be irradiated with more conformal techniques. Traditional forms of radiation in particular pose challenges for combination trials with immunotherapy. This chapter explores these issues in more detail and provides insights as to how radiation therapy can be optimized t
36#
發(fā)表于 2025-3-27 18:04:11 | 只看該作者
Frank Lettke auditory complications can lead to speech recognition deficits and sensorineural hearing loss. Ocular toxicities are among the most common adverse events resulting from the use of these agents. The majority of ocular immune-related adverse events (irAEs) are mild, low-grade, non-sight threatening,
37#
發(fā)表于 2025-3-28 01:25:04 | 只看該作者
38#
發(fā)表于 2025-3-28 02:46:10 | 只看該作者
39#
發(fā)表于 2025-3-28 08:14:48 | 只看該作者
Heinz Blaumeiser,Thomas Klie development to predict response to immunotherapy and risk of toxicity. This book chapter is a comprehensive review of immunotherapeutic approaches, both approved and investigational, for the treatment of renal cell carcinoma, urothelial carcinoma, and prostate cancer.
40#
發(fā)表于 2025-3-28 11:37:24 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 18:37
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
锡林郭勒盟| 章丘市| 卢氏县| 苍南县| 浪卡子县| 崇明县| 浦城县| 和林格尔县| 搜索| 芒康县| 新丰县| 方山县| 聂拉木县| 庆元县| 喀喇| 资溪县| 会同县| 天水市| 松原市| 临漳县| 祁东县| 咸阳市| 卢湾区| 习水县| 通化市| 永善县| 尖扎县| 含山县| 常熟市| 靖西县| 四川省| 曲靖市| 嘉义市| 和林格尔县| 永胜县| 贡觉县| 靖西县| 璧山县| 鹿邑县| 兰溪市| 泗洪县|